Abstract：Objective To investigate the relationship between platelet-to-lymphocyte ratio (PLR) and clinicopathological features and postoperative recurrence risk of gastrointestinal stromal tumors.MethodsThe clinicopathological data of 92 patients with gastrointestinal stromal tumors treated in the Gastrointestinal Surgery of Beijing Hospital from January 2006 to December 2011 were retrospectively analyzed. The PLR values were calculated and the receiver operating characteristic (ROC) curve and Youden index were used to determine the cut-off value of the PLR. The clinicopathological characteristics and postoperative recurrence risk between the two groups were analyzed. Subgroup analysis was performed on the basis of National Institutes of Health risk criteria according to preoperative and postoperative PLR cutoff values.Results The average preoperative and postoperative PLR of 92 patients were 148.4±70.5 and 206.7±115.3, respectively. When the preoperative and postoperative PLR value were 167.2 and 175.2 respectively, the Youden index were the largest, the sensitivities were 61.9% and 85.7%, respectively, and the specificities were 76.1% and 54.9%, respectively. Patients were divided into preoperative low PLR group (62/92, 67.4%) and preoperative high PLR group (30/92, 32.6%) based on the cut-off value of 167.2. Patients were divided into postoperative low PLR group (42/92, 45.7%) and postoperative high PLR group (50/92, 54.3%) based on the cut-off value of 175.2. The 1, 3, and 5-year recurrence-free survival rates in the preoperative high PLR group were 90.0%, 69.9% and 40.4% respectively. The 1, 3, and 5-year recurrence-free survival rates in the preoperative low PLR group were 96.8%, 89.9% and 75.6%, respectively, and the difference was statistically significant (χ2=7.461, P＜0.05). The 1, 3, and 5-year recurrence-free survival rates in the postoperative high PLR group were 94.0%, 71.3% and 45.3%, respectively. The 1, 3, and 5-year recurrence-free survival rates in the preoperative low PLR group were 97.6%, 93.4% and 83.0%, respectively, and the difference was statistically significant (χ2=9.894, P＜0.05). Multivariate analysis showed that the high risk of tumor classification and preoperative PLR≥167.2 were independent risk factors affecting the 5-year recurrence-free survival rates of GIST patients (all P values＜0.05).Conclusions PLR can better reflect postoperative recurrence risk of gastrointestinal stromal tumors, and might be a valuable marker for recurrence risk assessment of gastrointestinal stromal tumors.
赵刚, 曹祥龙. 血小板与淋巴细胞比值在胃肠间质瘤复发风险评估中的应用价值[J]. 中华解剖与临床杂志, 2019, 24(1): 58-64.
Zhao Gang, Cao Xianglong. The value of platelet-to-lymphocyte ratio for evaluation of recurrence risk in patients with gastrointestinal stromal tumor. Chinese Journal of Anatomy and Clinics, 2019, 24(1): 58-64.
Saito H, Kono Y, Murakami Y, et al. Prognostic significance of platelet-based inflammatory indicators in patients with gastric cancer[J]. World J Surg, 2018, 42(8): 2542-2550. DOI: 10.1007/s00268-018-4527-8
[2]
Zhao QT, Yuan Z, Zhang H, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients[J]. Int J Cancer, 2016,139(1):164-170. DOI: 10.1002/ijc.30060
Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor[J]. Chin J Cancer Res, 2017, 29(4): 281-293. DOI:10.21147/j.issn.1000-9604.2017.04.01
[6]
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis 1987, 40(5): 373-383
[7]
Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts[J]. Lancet Oncol, 2012,13(3): 265-274. DOI:10.1016/S1470-2045(11)70299-6
[8]
Dupré A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know[J]. Eur J Surg Oncol, 2018, 44(5): 566-570. DOI:10.1016/j.ejso.2018.02.209
[9]
Peng HX, Lin K, He BS, et al. Platelet-to-lymphocyte ratio could be a promising prognostic biomarker for survival of colorectal cancer: a systematic review and meta-analysis[J]. FEBS Open Bio, 2016, 6(7): 742-750. DOI:10.1002/2211-5463.12083
[10]
Goh BK, Chok AY, Allen JC Jr, et al. Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors[J]. Surgery, 2016, 159(4): 1146-56. DOI:10.1016/j.surg.2015.10.021
[11]
Lam M, Roszik J, Kanikarla-Marie P, et al. The potential role of platelets in the consensus molecular subtypes of colorectal cancer[J]. Cancer Metastasis Rev, 2017, 36(2): 273-288. DOI:10.1007/s10555-017-9678-9
[12]
Perez DR, Baser RE, Cavnar MJ, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor[J]. Ann Surg Oncol, 2013, 20(2): 593-599. DOI:10.1245/s10434-012-2682-y.
2019, Vol. 24 
